Gradientech carries out a rights issue of approximately SEK 57 million
The Board of Directors of Gradientech AB (publ) (“Gradientech” or “the Company”) decided on 26 February 2026 to carry out a new issue of shares with preferential rights for existing shareholders of approximately SEK 57 million (the “Rights Issue”). A prospectus regarding the Rights Issue will after approval by the Swedish Financial Supervisory Authority be available on the Company's website gradientech.se (https://gradientech.se/investors/).
Investor presentations
Shareholders are invited to participate in Gradientech’s investor presentations via Teams at the following times:
11 March, 11.00-11.30 CET
12 March, 17.00-17.30 CET
16 March, 15.00-15.30 CET
Further information and links to the presentation events will be made available on the Company’s website and distributed digitally to the Company’s shareholders following approval of the prospectus.
Terms for the Rights Issue
Those registered as a shareholder on the record date of 5 March 2026, has a preferential right to subscribe for ordinary shares in the Rights Issue in relation to the number of ordinary shares held on the record date. One (1) existing share in the Company entitles to one (1) subscription right. Five (5) subscription rights entitle to subscribe for one (1) new share.
The subscription price is SEK 8.75 per new share. If the offer is fully subscribed, the number of shares in the Company will increase from 32,331,232 shares to 38,797,478 shares, corresponding to a dilution effect of approximately 17 percent. Subscription of shares shall take place during the period from and including 9 March 2026 to and including 23 March 2026. The Board has the right to extend the subscription and payment period. Aqurat Fondkommission AB acts as an issuing agent in connection with the Rights Issue.
Subscription commitments
In connection with the Rights Issue, the Company has received subscription commitments totalling approximately SEK 39 million, corresponding to approximately 69 percent of the Rights Issue. No compensation is paid for submitted subscription commitments.
Prospectus
Complete terms and conditions for the Rights Issue as well as other information about the Company and information about subscription commitments appear in the prospectus and will be available on the Company’s and the Swedish Financial Supervisory Authority respective websites after approval by the Swedish Financial Supervisory Authority (gradientech.se, fi.se).
For further information, please contact:
Sara Thorslund, CEO
Urban Adolfsson, CFO
Tel: + 46 708 20 72 09
About Gradientech
Gradientech is a leader in ultra-rapid antibiotic susceptibility testing, developing next-generation diagnostics for infectious disease medicine. Our innovative diagnostic solutions aim to save lives, reduce healthcare costs, and combat the spread of antibiotic resistance – one of our greatest global health threats. Gradientech is headquartered in Uppsala, Sweden. Visit gradientech.se for more information.